17. Ovarian tumor cells gain competitive advantage by actively reducing the cellular fitness of microenvironment cells
In a collaborative effort led by Esha Madan and Rajan Gogna from Virginia Commonwealth University School of Medicine in USA, a novel cancer therapy approach and target has been identified specifically reducing the cellular fitness of microenvironmental cells in ovarian cancer. This impressive work, including three Iscaff researchers as co-authors, is now published in the prestigious and top-ranked journal Nature Biotechnology. The patient-derived scaffold model developed by Iscaff Pharma was an important tool within the project to fully secure the clinical relevance for the cancer therapy strategy. This ground-breaking work clearly illustrate the usefulness and demand for the Iscaff-technology in modern drug discovery and development.
